Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders purchased 1,002 put options on the stock. This is an increase of 1,791% compared to the typical daily volume of 53 put options.
Analyst Ratings Changes
A number of research analysts have recently commented on MRVI shares. Morgan Stanley lowered their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Tuesday, March 25th. Baird R W lowered Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a research report on Friday, March 21st. UBS Group lowered their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research report on Friday, March 21st. Finally, Bank of America dropped their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of "Hold" and an average target price of $6.34.
View Our Latest Report on MRVI
Maravai LifeSciences Stock Up 9.0 %
NASDAQ MRVI traded up $0.16 during mid-day trading on Tuesday, reaching $1.93. The stock had a trading volume of 3,156,834 shares, compared to its average volume of 2,368,504. The stock has a market cap of $490.87 million, a PE ratio of -1.18 and a beta of 0.18. Maravai LifeSciences has a 1 year low of $1.67 and a 1 year high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a fifty day moving average price of $2.58 and a 200 day moving average price of $4.74.
Insider Activity
In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares of the company's stock, valued at $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.63% of the company's stock.
Institutional Trading of Maravai LifeSciences
A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company's stock valued at $33,658,000 after buying an additional 3,731,924 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of Maravai LifeSciences by 145.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock valued at $29,045,000 after acquiring an additional 3,161,072 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Maravai LifeSciences by 17,912.9% in the fourth quarter. Marshall Wace LLP now owns 2,778,497 shares of the company's stock worth $15,143,000 after acquiring an additional 2,763,072 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Maravai LifeSciences by 29.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock valued at $25,420,000 after purchasing an additional 1,062,485 shares during the last quarter. Finally, CenterBook Partners LP bought a new position in Maravai LifeSciences during the fourth quarter valued at approximately $4,425,000. Institutional investors own 50.25% of the company's stock.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
